Highlights…
This month's top story discusses a meta-analysis that concludes that present evidence does not support routine clinical use of quantitative electroencephalography (QEEG) to predict response to depression treatment. Lack of cross-validation plagues many of the existing studies of QEEG, the authors suggest. 
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DepressIon treatment
Insufficient evidence to predict depression treatment response with quantitative EEG A retrospective cohort study of patients with a history of attention-deficit/hyperactivity disorder (ADHD) has found an increased risk of Parkinson's disease and related disorders in this group. The increased risk was especially pronounced in individuals who were prescribed psychostimulants such as amphetamine and methylphenidate for treatment of ADHD.
Research has shown that heavy exposure to methamphetamine causes dopaminergic deficits in the basal ganglia that can exacerbate risk of Parkinson's disease. Less is known, however, about the effect of longterm exposure to psychostimulant therapy for A meta-analysis of research examining the ability of quantitative electroencephalography (QEEG) to predict response to treatment for depression has concluded that the technique lacks clinical reliability. The research team for this meta-analysis cited small sample sizes and a lack of cross-validation among the common study deficiencies that led them to their conclusion.
Ongoing uncertainty over which treatment option for depression will work best for a particular patient underscores the need for reliable biomarkers for predicting treatment response. One approach that has long been of interest is QEEG, which analyzes EEG results through standardized aDhD treatment , an assistant professor of psychiatry at the University of Minnesota, conducted a meta-analysis of QEEG that examined its evidence base in predicting response to treatment for depression. The meta-analysis also evaluated the degree to which published studies implemented practices that support reproducibility and reliability.
Study methods
The researchers conducted a PubMed search for articles related to EEG, major depression, and response prediction, selecting those that reported prediction of response to any treatment using any EEG metric. The inclusion criteria were purposely broad in order to test the researchers' hypothesis that QEEG cannot reliably predict treatment response. The researchers selected the predictor with the highest positive predictive value in studies that reported multiple methods of analyzing the same biomarker.
In evaluating the quality of studies, the researchers focused primarily on use of the analytic method of cross-validation, in which a biomarker is tested on a subset of patients who were not involved in the process of developing the marker. This can help determine if the research has identified a marker that would work well in a wide variety of patients with depression.
Results
Fifty-three research articles encompassing 57 QEEG biomarkers and 81 studies contained information sufficient for inclusion in the meta-analysis. Seventy percent of the studies addressed predictors of response to medication for depression, with citalopram/escitalopram and venlafaxine the most commonly studied drugs.
Study sizes were generally small, with a median of 25 participants. Most of the studies did not meet accepted metrics of quality, with only 8% using either crossvalidation or another out-of-sample means of verification.
The meta-analysis suggests although QEEG as a technique may have potential for predicting antidepressant treatment response, no QEEG biomarker has significantly greater power than any other. Funnel-plot analysis found that the predictive power of QEEG is driven by small studies with strong positive results. The researchers concluded that the evidence so far does not support routine clinical use of QEEG as a predictive biomarker for treatment response in depression.
Implications
Widge told The Update that he had been involved in two earlier studies that failed to separate treatment responders from nonresponders with use of proposed biomarkers. He said that much of the existing research into potential biomarkers for depression treatment response is marred by either small sample sizes or lack of independent testing. "Depression is a complex disease with a lot of internal variation," Widge said. "With those small samples, it's hard to really adequately sample across the variation and make sure a marker will work for a wide variety of depression cases." In addition, he said, "Because depression is so heterogeneous, you have to test candidate markers in a fresh sample of patients who weren't used to discover/design the marker."
Widge and colleagues wrote, "Use of commercial or research-grade QEEG methods in routine clinical practice would not be a wise use of health care dollars." Widge emphasized, however, that this does not mean QEEG never could be shown to be effective, only that the quality of research to date does not allow for a definitive answer. He and his colleagues pointed out that their results do not suggest that further research into QEEG's predictive potential should be stopped.
For any biomarker research in psychiatry, Widge said, future studies need to use larger sample sizes, apply cross-validation or similar techniques prior to publication, and be reviewed by someone other than individuals who developed the marker. "We only ever really know something is trustworthy if it works outside the original authors' hands," Widge said. ▪
Two study co-authors have pending patent applications related to the use of electrographic markers to assess patients and select neuromodulation therapies, and several co-authors reported research support and/or consulting arrangements with pharmaceutical companies. Researchers led by Karen Curtin, of the Department of Internal Medicine at the University of Utah School of Medicine, conducted a retrospective cohort study to determine whether ADHD or its treatment is associated with an increased incidence of diseases of the basal ganglia and cerebellum. The researchers placed a special emphasis on individuals ages 21 to 49, the period defining early-onset Parkinson's disease.
Study methods
The researchers accessed the Utah Population Database to examine records for all individuals born between 1950 and 1992. They excluded from the analysis all individuals with an HIV diagnosis, because HIV can generate Parkinson's-like symptoms. They also excluded individuals with a drug or alcohol abuse history in order to avoid potential confounding from the presence of a substance use disorder.
A total of 31,769 patients comprised the ADHD cohort, with 4,960 of those individuals having been prescribed a stimulant (mixed amphetamine salts were the most common medication prescribed). A total of 158,790 individuals with no history of ADHD or diseases of the basal ganglia were individually matched to ADHD patients.
The researchers measured time from baseline to an index diagnosis on or before Dec. 31, 2016, of any adult-onset disease of the basal ganglia and cerebellum, 
